Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study
Sarris J, Stough C, Bousman CA, Wahid ZT, Murray G, Teschke R, Savage KM, Dowell A, Ng C, Schweitzer I
Published in Journal of Clinical Psychopharmacology
Methodology
Six-week double-blind randomised placebo-controlled trial of aqueous kava extract in 75 participants with generalised anxiety disorder, with GABA transporter polymorphism analysis
Key Findings
Kava significantly reduced anxiety versus placebo with a moderate effect size and no clinically significant hepatotoxicity over six weeks.
Conclusions
Short-term aqueous kava reduced generalised anxiety symptoms in a controlled trial.
Limitations
Short duration; modest sample; later larger trial did not replicate.
Supplements Studied
Kava significantly reduced anxiety versus placebo with a moderate effect size and no clinically significant hepatotoxicity over six weeks.
Outcomes Measured
Kava significantly reduced anxiety versus placebo with a moderate effect size and no clinically significant hepatotoxicity over six weeks.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.